Clinical Trial Search

Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate

Primary: Antimicrobial Resistance (AMR) of Conjunctiva at 1 Week — 0; 0; 0 reads per million reads — p=1

Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05

Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants

Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026

Primary: Subjects Who Developed Antibiotic Resistance Organisms — 0; 0; 1; 0 Participants

Primary: Duration of Hospitalization — 14.1 Days

Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant

Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers

Primary: Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome — 10.2; 8.8; 9.7; 9.6 Index score

Primary: Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit — 21.2; 20.9; 19.1; 21.6 percentage of visits prescribed an abx — p=0.35

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants

Primary: Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day — 68616; 68679; 76605; 50001 Extended-Spectrum Days-of-Therapy

Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants

Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants

Primary: Inappropriate Antibiotic Prescribing Rate for Qualifying Acute Respiratory Infection Diagnoses — 0.20; 0.19; 0.08; 0.09 proportion of visits

Primary: Number of Participants With Adverse Events (NIH Grade ≥2) at Day 7 After Randomization — 4; 0 Participants

Primary: Number of Environmentally-implicated Healthcare-Associated Infections (eiHAIs) Associated With the Additional Use of a PX-UV Disinfection Compared to Standard Terminal…

Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008

Primary: Percentage of Participants With Favorable Overall Response (FOR) — 71.4; 70.0 Percentage of Participants

Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants

Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17

Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05

Primary: Surgical Site Infection — 11; 10 Participants

Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit - Microbiologically Modified Intent-to-Treat (mMITT) Analysis Set — 59.3; 25.9 Percentage of…

Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants

Primary: Imipenem Clearance — 17.31 L/h

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Primary: Treatment Success of Group A (2 Doses of RBX2660) vs Group B (2 Doses of Placebo) (ITT) — 25; 19; 20; 25 Participants